Acadian Asset Management
SXTC icon

Acadian Asset Management’s China SXT Pharmaceuticals SXTC Stock Holding History

Acadian Asset Management’s Portfolio SXTC Stock Details SXTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Hold
0
– – – 2001
2025
Q2 		– Hold
0
– – – 1827
2025
Q1 		– Hold
0
– – – 1808
2024
Q4 		– Hold
0
– – – 2146
2024
Q3 		– Sell
-2
Closed -$2.17K – 2326
2024
Q2 		$2K Hold
2
– – ﹤0.01% 1723
2024
Q1 		$3K Hold
2
– – ﹤0.01% 1536
2023
Q4 		$10K Sell
2
-2
-50% -$5.57K ﹤0.01% 1624
2023
Q3 		$12K Hold
4
– – ﹤0.01% 1586
2023
Q2 		$23K Hold
4
– – ﹤0.01% 1636
2023
Q1 		$28K Buy
4
+2
+100% +$26.9K ﹤0.01% 1603
2022
Q4 		$24K Buy
+2
New +$38.4K ﹤0.01% 1696
2022
Q2 		– Hold
0
– -$31K – 1851
2022
Q1 		– Hold
0
– – – 1520
2020
Q4 		– Hold
0
– -$14K – 2351
2020
Q3 		– Hold
0
– – – 2107
2020
Q2 		– Hold
0
– – – 1170
2020
Q1 		– Hold
0
– – – 1707

Other funds holding SXTC

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
SOW
State of Wyoming Cheyenne, Wyoming $989M AUM 52.24% 1-Year Est. Return

Acadian Asset Management's SXTC Position: Q3 2025 in Review

Acadian Asset Management held its China SXT Pharmaceuticals (SXTC) position steady in Q3 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2001.

Acadian Asset Management first reported a position in SXTC in Q4 2022 and has held it in 7 quarters since. The position peaked at $28K in Q1 2023. 10 funds tracked by Wall St. Rank hold SXTC as of Q3 2025.

  • Acadian Asset Management held 0 shares of China SXT Pharmaceuticals worth $0 as of Q3 2025.
  • Acadian Asset Management left its China SXT Pharmaceuticals share count unchanged in Q3 2025.
  • China SXT Pharmaceuticals made up ﹤0.01% of Acadian Asset Management's portfolio in Q3 2025, its #2001 holding.
  • Acadian Asset Management first reported a position in China SXT Pharmaceuticals in Q4 2022 and has held it in 7 quarters since.
  • Acadian Asset Management's China SXT Pharmaceuticals position peaked at $28K in Q1 2023.
  • 10 funds tracked by Wall St. Rank held China SXT Pharmaceuticals as of Q3 2025.

Based on Acadian Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.